Journal Title：Translational Cancer Research

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

轉化癌癥研究 (Transl Cancer Res TCR；印刷 ISSN：2218-676X；在線 ISSN 2219-6803；http://tcr.amegroups.com/) 是一本開放獲取、同行評審的期刊，收錄于科學引文索引擴展版 (SCIE)。TCR 發表新型治療干預的實驗室研究以及評估癌癥新治療模式的臨床試驗；新型研究調查的結果，這些調查將實驗室和臨床環境連接起來，包括風險評估、細胞和分子表征、人類癌癥的預防、檢測、診斷和治療，總體目標是改善癌癥患者的臨床護理。TCR 的重點是原創的、同行評審的、基于科學的研究，這些研究成功地推動了臨床醫學朝著改善患者生活質量的目標發展。編輯和由科學家、臨床科學家以及其他專家組成的國際顧問團將確保 TCR 文章達到高質量標準。我們接受原創文章以及評論文章、社論和簡短文章。

Translational Cancer Research創刊于2012年，由AME Publishing Company出版商出版，收稿方向涵蓋ONCOLOGY全領域，此期刊水平偏中等偏靠后，在所屬細分領域中專業影響力一般，過審相對較易，如果您文章質量佳，選擇此期刊，發表機率較高。平均審稿速度 ，影響因子指數1.5，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。